HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krahn, M Articles by Detsky, A S Search for Related Content PubMed PubMed Citation Articles by Krahn, M Articles by Detsky, A S

Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.

M Krahn, R Guasparini, M Sherman and A S Detsky

Department of Medicine, University of Toronto, Ontario, Canada. murray.krahn@utoronto.ca

OBJECTIVES: This study evaluated the costs and cost-effectiveness of a school-based grade 6 universal vaccination program against hepatitis B. METHODS: We performed a descriptive cost study and cost-effectiveness analysis of British Columbia's vaccination program for 1994 and 1995. Since 1992, public health nurses have administered hepatitis B vaccine to grade 6 students in schools. We measured costs of vaccine, vaccine administration, and net program costs and used a validated Markov model to calculate the cost-effectiveness of the program. RESULTS: Vaccinating each student cost $44, $24 of which was the cost of vaccine administration. The net cost was $9 per person; considering productivity costs, net savings were $75 per person. Marginal cost per life year gained was $2100. Universal adolescent vaccination is also economically attractive in the United States but less attractive in regions with incidence rates below 3 cases per 100,000 per year. CONCLUSIONS: Hepatitis B vaccine can be delivered in North American schools at a reasonable cost. Adolescent vaccination is economically attractive in North American regions of high and average incidence rates. Our analysis supports vaccination in adolescents who remain at risk for hepatitis B virus infection.

This article has been cited by other articles:

				L. Tilson, L. Thornton, D. O'Flanagan, H. Johnson, and M. Barry Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation Eur J Public Health, June 1, 2008; 18(3): 275 - 282. [Abstract] [Full Text] [PDF]

				J. Schmier, S. Li, J. C. King Jr., K. Nichol, and P. J. Mahadevia Benefits And Costs Of Immunizing Children Against Influenza At School: An Economic Analysis Based On A Large-Cluster Controlled Clinical Trial Health Aff., March 1, 2008; 27(2): w96 - w104. [Abstract] [Full Text] [PDF]

				I. R. Ortega-Sanchez, G. M. Lee, R. J. Jacobs, L. A. Prosser, N.-A. Molinari, X. Zhang, W. B. Baine, M. M. McCauley, T. Miller, and for the Working Group on Leading Economic Issues f Projected Cost-effectiveness of New Vaccines for Adolescents in the United States Pediatrics, January 1, 2008; 121(Supplement_1): S63 - S78. [Abstract] [Full Text] [PDF]

				D. W. Hutton, D. Tan, S. K. So, and M. L. Brandeau Cost-Effectiveness of Screening and Vaccinating Asian and Pacific Islander Adults for Hepatitis B Ann Intern Med, October 2, 2007; 147(7): 460 - 469. [Abstract] [Full Text] [PDF]

				M. B. Rothberg, D. Fisher, B. Kelly, and D. N. Rose Management of Influenza Symptoms in Healthy Children: Cost-effectiveness of Rapid Testing and Antiviral Therapy Arch Pediatr Adolesc Med, November 1, 2005; 159(11): 1055 - 1062. [Abstract] [Full Text] [PDF]

				S. J. Goldie, M. Kohli, D. Grima, M. C. Weinstein, T. C. Wright, F. X. Bosch, and E. Franco Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine J Natl Cancer Inst, April 21, 2004; 96(8): 604 - 615. [Abstract] [Full Text] [PDF]

				H. P. Levaux, W. H. Schonfeld, J. M. Pellissier, W. M. Cassidy, S. K. Sheriff, and C. Fitzsimon Economic Evaluation of a 2-Dose Hepatitis B Vaccination Regimen for Adolescents Pediatrics, August 1, 2001; 108(2): 317 - 325. [Abstract] [Full Text] [PDF]

				R. J. Jacobs, H. S. Margolis, and P. J. Coleman The Cost-effectiveness of Adolescent Hepatitis A Vaccination in States With the Highest Disease Rates Arch Pediatr Adolesc Med, August 1, 2000; 154(8): 763 - 770. [Abstract] [Full Text] [PDF]

				L. B. Russell How Treatment Advances Affect Prevention's Cost-Effectiveness: Implications for the Funding of Medical Research Med Decis Making, July 1, 2000; 20(3): 352 - 354. [PDF]

				J. M. Wiecha Differences in Knowledge of Hepatitis B Among Vietnamese, African- American, Hispanic, and White Adolescents in Worcester, Massachusetts Pediatrics, November 1, 1999; 104(5): 1212 - 1216. [Abstract] [Full Text]